Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHSCT vs Rituximab in Refractory SLE
NCT05063513Phase 3Withdrawn
- Start
- Jul 2009
- Primary completion
- Jul 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous hematopoietic stem cells in systemic lupus erythematosus (SLE) (2 arms). Primary endpoint: Remission Induction Efficacy at 2 years. Planned start Jul 2009; status: withdrawn.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05063513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063513.